NEW YORK, Nov. 5, (GenomeWeb News) - South San Francisco-based Exelixis reported $12.4 million in revenues for the third quarter ending Sept. 30, up over revenues of $10.4 million for the same period in 2002.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.